Reindl M - Search Results

1

Impact of glatiramer acetate on paraclinical markers of neuroprotection in multiple sclerosis: A prospective observational clinical trial.

Ehling R, Di Pauli F, Lackner P, Rainer C, Kraus V, Hegen H, Lutterotti A, Kuenz B, De Zordo T, Schocke M, Glatzl S, Löscher WN, Deisenhammer F, Reindl M, Berger T. Ehling R, et al. Among authors: reindl m. J Neuroimmunol. 2015 Oct 15;287:98-105. doi: 10.1016/j.jneuroim.2015.08.004. Epub 2015 Aug 10. J Neuroimmunol. 2015. PMID: 26439969 Clinical Trial.

2

Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies.

Deisenhammer F, Reindl M, Harvey J, Gasse T, Dilitz E, Berger T. Deisenhammer F, et al. Among authors: reindl m. Neurology. 1999 Apr 12;52(6):1239-43. doi: 10.1212/wnl.52.6.1239. Neurology. 1999. PMID: 10214750

3

Increased expression of apolipoprotein D following experimental traumatic brain injury.

Franz G, Reindl M, Patel SC, Beer R, Unterrichter I, Berger T, Schmutzhard E, Poewe W, Kampfl A. Franz G, et al. Among authors: reindl m. J Neurochem. 1999 Oct;73(4):1615-25. doi: 10.1046/j.1471-4159.1999.0731615.x. J Neurochem. 1999. PMID: 10501208 Free article.

4

Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study.

Reindl M, Linington C, Brehm U, Egg R, Dilitz E, Deisenhammer F, Poewe W, Berger T. Reindl M, et al. Brain. 1999 Nov;122 ( Pt 11):2047-56. doi: 10.1093/brain/122.11.2047. Brain. 1999. PMID: 10545390 Clinical Trial.

5

A critical comparison of frequently used methods for the analysis of tumor necrosis factor-alpha expression by human immune cells.

Mayringer I, Reindl M, Berger T. Mayringer I, et al. Among authors: reindl m. J Immunol Methods. 2000 Feb 21;235(1-2):33-40. doi: 10.1016/s0022-1759(99)00208-2. J Immunol Methods. 2000. PMID: 10675755

6

A comparative study of the relative bioavailability of different interferon beta preparations.

Deisenhammer F, Mayringer I, Harvey J, Dilitz E, Gasse T, Stadlbauer D, Reindl M, Berger T. Deisenhammer F, et al. Among authors: reindl m. Neurology. 2000 Jun 13;54(11):2055-60. doi: 10.1212/wnl.54.11.2055. Neurology. 2000. PMID: 10851362 Clinical Trial.

7

Immunopathogenic and clinical relevance of antibodies against myelin oligodendrocyte glycoprotein (MOG) in Multiple Sclerosis.

Berger T, Reindl M. Berger T, et al. Among authors: reindl m. J Neural Transm Suppl. 2000;(60):351-60. doi: 10.1007/978-3-7091-6301-6_25. J Neural Transm Suppl. 2000. PMID: 11205153 Review.

8

The fine specificity of the myelin oligodendrocyte glycoprotein autoantibody response in patients with multiple sclerosis and normal healthy controls.

Haase CG, Guggenmos J, Brehm U, Andersson M, Olsson T, Reindl M, Schneidewind JM, Zettl UK, Heidenreich F, Berger T, Wekerle H, Hohlfeld R, Linington C. Haase CG, et al. Among authors: reindl m. J Neuroimmunol. 2001 Mar 1;114(1-2):220-5. doi: 10.1016/s0165-5728(00)00462-8. J Neuroimmunol. 2001. PMID: 11240035

9

Immunoglobulin subclasses in patients with neutralizing and nonneutralizing antibodies against IFN-beta1b.

Deisenhammer F, Reindl M, Berger T. Deisenhammer F, et al. Among authors: reindl m. J Interferon Cytokine Res. 2001 Mar;21(3):167-71. doi: 10.1089/107999001750133195. J Interferon Cytokine Res. 2001. PMID: 11331039

10

Increased intrathecal production of apolipoprotein D in multiple sclerosis.

Reindl M, Knipping G, Wicher I, Dilitz E, Egg R, Deisenhammer F, Berger T. Reindl M, et al. J Neuroimmunol. 2001 Oct 1;119(2):327-32. doi: 10.1016/s0165-5728(01)00378-2. J Neuroimmunol. 2001. PMID: 11585636

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

421 results

Search Page

Filters